Geographical similarity and differences in the burden and genetic predisposition of NAFLD
- PMID: 36062393
- DOI: 10.1002/hep.32774
Geographical similarity and differences in the burden and genetic predisposition of NAFLD
Abstract
NAFLD has become a major public health problem for more than 2 decades with a growing prevalence in parallel with the epidemic of obesity and type 2 diabetes (T2D). The disease burden of NAFLD differs across geographical regions and ethnicities. Variations in prevalence of metabolic diseases, extent of urban-rural divide, dietary habits, lifestyles, and the prevalence of NAFLD risk and protective alleles can contribute to such differences. The rise in NAFLD has led to a remarkable increase in the number of cases of cirrhosis, hepatocellular carcinoma, hepatic decompensation, and liver-related mortality related to NAFLD. Moreover, NAFLD is associated with multiple extrahepatic manifestations. Most of them are risk factors for the progression of liver fibrosis and thus worsen the prognosis of NAFLD. All these comorbidities and complications affect the quality of life in subjects with NAFLD. Given the huge and growing size of the population with NAFLD, it is expected that patients, healthcare systems, and the economy will suffer from the ongoing burden related to NAFLD. In this review, we examine the disease burden of NAFLD across geographical areas and ethnicities, together with the distribution of some well-known genetic variants for NAFLD. We also describe some special populations including patients with T2D, lean patients, the pediatric population, and patients with concomitant liver diseases. We discuss extrahepatic outcomes, patient-reported outcomes, and economic burden related to NAFLD.
Copyright © 2023 American Association for the Study of Liver Diseases.
Similar articles
-
Changing epidemiology, global trends and implications for outcomes of NAFLD.J Hepatol. 2023 Sep;79(3):842-852. doi: 10.1016/j.jhep.2023.04.036. Epub 2023 May 9. J Hepatol. 2023. PMID: 37169151 Review.
-
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103. World J Gastroenterol. 2015. PMID: 25892859 Free PMC article. Review.
-
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):330-44. doi: 10.1038/nrgastro.2013.41. Epub 2013 Mar 19. Nat Rev Gastroenterol Hepatol. 2013. PMID: 23507799 Review.
-
Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease in Endocrinology Clinics.Endocr Pract. 2023 Nov;29(11):912-918. doi: 10.1016/j.eprac.2023.06.012. Epub 2023 Jul 3. Endocr Pract. 2023. PMID: 37406857 Review.
-
Epidemiology of non-alcoholic fatty liver disease in Asia.Indian J Gastroenterol. 2020 Feb;39(1):1-8. doi: 10.1007/s12664-020-01018-x. Epub 2020 Mar 9. Indian J Gastroenterol. 2020. PMID: 32152903 Review.
Cited by
-
Free triiodothyronine and triglyceride-glucose index interaction on metabolic dysfunction-associated steatotic liver disease risk in euthyroid individuals.Front Endocrinol (Lausanne). 2025 Apr 24;16:1526198. doi: 10.3389/fendo.2025.1526198. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40343070 Free PMC article.
-
Genetic Polymorphisms and Diversity in Nonalcoholic Fatty Liver Disease (NAFLD): A Mini Review.Biomedicines. 2022 Dec 30;11(1):106. doi: 10.3390/biomedicines11010106. Biomedicines. 2022. PMID: 36672614 Free PMC article. Review.
-
Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges.Int J Mol Sci. 2023 Feb 26;24(5):4583. doi: 10.3390/ijms24054583. Int J Mol Sci. 2023. PMID: 36902015 Free PMC article. Review.
-
Dietary inflammatory impact on NAFLD development in obese vs. lean individuals: an analysis based on NHANES 2003-2018.Lipids Health Dis. 2024 Apr 29;23(1):127. doi: 10.1186/s12944-024-02082-4. Lipids Health Dis. 2024. PMID: 38685122 Free PMC article.
-
Global Epidemiology and Implications of PNPLA3 I148M Variant in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-analysis.J Clin Exp Hepatol. 2025 May-Jun;15(3):102495. doi: 10.1016/j.jceh.2024.102495. Epub 2024 Dec 26. J Clin Exp Hepatol. 2025. PMID: 39882540 Review.
References
-
- Powell EE, Wong VW, Rinella M. Non‐alcoholic fatty liver disease. Lancet. 2021;397:2212–2224.
-
- NCD Risk Factor Collaboration (NCD‐RisC). Worldwide trends in body‐mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population‐based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017;390:2627–42.
-
- NCD Risk Factor Collaboration (NCD‐RisC). Rising rural body‐mass index is the main driver of the global obesity epidemic in adults. Nature. 2019;569:260–4.
-
- Estes C, Anstee QM, Arias‐Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016‐2030. J Hepatol. 2018;69:896–904.
-
- Estes C, Chan HLY, Chien RN, Chuang WL, Fung J, Goh GBB, et al. Modelling NAFLD disease burden in four Asian regions‐2019–2030. Aliment Pharmacol Ther. 2020;51:801–11.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical